Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients.

Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med (1999) 4.38

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology (2007) 3.73

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology (2012) 3.54

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med (2000) 3.44

Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol (2012) 2.91

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83

Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology (1994) 2.26

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol (2012) 2.14

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med (1998) 2.01

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology (1999) 1.99

Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology (1990) 1.72

Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology (2010) 1.44

Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut (2004) 1.17

Aging of patients with hepatitis C virus-associated hepatocellular carcinoma: long-term trends in Japan. Oncol Rep (2006) 0.97

Epidemiology of hepatitis C virus in japan. Intervirology (1999) 0.91

Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol (2007) 0.86

Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res (2016) 0.83

Recent trends of Japanese hepatocellular carcinoma due to HCV in aging society. Hepatogastroenterology (2012) 0.79

Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol (2016) 0.79